Improve Outcomes.
Reduce Adverse Events.
Lower Costs.

DoseMe is designed for healthcare
practitioners to improve patient care
by simplifying personalised dosing.

"What an amazing export.
Creating jobs."

— Prime Minister of Australia, Malcolm Turnbull,
with DoseMe founder Robert McLeay at
River City Labs conference June 2016.

DoseMe Voted #1
Most Opportunity for Global Expansion

DoseMe recognised at the inaugural 2016 Advance Queensland
Innovation and Investment Summit Gala as Qld startup with
the most global expansion opportunity.

(From Left: Queensland Treasurer, Hon Curtis Pitt; DoseMe Founder, Dr Robert McLeay; Queensland Premier, Hon Annastacia Palaszczuk)
--> Start Improving Patient Outcomes Now
Personalised Medicine: Making Complex Simple

DoseMe is easy-to-use software that allows clinicians to dose a patient based upon their ability to absorb, process, and clear a drug. Learn about the importance of individualised dosing by examining the impact of personalising dosing using DoseMe.

Improve Outcomes

Personalised dosing has been shown to be beneficial for drugs from antibiotics to chemotherapeutics to more. Learn more here.

Reduce Adverse Events

Dose-individualisation reduces adverse events, and has even been shown to halve side-effects in chemotherapy. See the research here.

Lower Costs

Personalised dosing has known and quantified cost-benefits, with up to a 52:1 cost-benefit ratio. View the studies here.

About DoseMe

DoseMe: Easy-To-Use Software

DoseMe is easy-to-use software that allows clinicians to dose a patient based upon that patient's individual ability to absorb, process, and clear a drug. DoseMe is CE marked for European use, and listed on the Australian Register of Therapeutic Goods. DoseMe is commercially available today for clinical use by healthcare professionals.

DoseMe supports clinical decision making in dosing a patient based upon that patient's individual ability to absorb, process, and clear a drug. Using more than basic patient information such as height, weight, and gender, DoseMe accurately calculates dosage based on the metabolism of individual patients - without requiring more laboratory tests than are currently performed. DoseMe learns how each patient responds to a drug - and continues to learn over time. By doing so, DoseMe provides true personalised medicine — and significantly improved dosing accuracy and patient outcomes.

Latest News and Updates

January 11, 2017

Carboplatin Released

Carboplatin (Adults only) will be available with a subscription to the Oncology Package. It is used in a wide variety of chemotherapy treatments including advanced ovarian cancer in combination with other chemotherapy.

Calculation methods of AUC24 and Peak Only are available.

December 13, 2016

DoseMe Partners with Microsoft

DoseMe is excited to announce our move to Azure cloud platform. Read about our new friendship here.

December 9, 2016

Imatinib Mesylate and Voriconazole Released

Imatinib Mesylate (Adult) and Voriconazole (Adult) drug models now available.

November 14, 2016

Meropenem IV (Adult) Released

Meropenem IV is now available in DoseMe to all antibiotic subscribers at no additional cost.

November 10, 2016

Delivering Precision Dosing to Australian Cancer Patients

DoseMe is pleased to announce a strategic alliance with specialist oncology eHealth provider, Charm Health, to integrate DoseMe personalised dosing tool with the CHARM platform.
Read the PulseIT article…

October 28, 2016

Methotrexate IV (Adult & Paediatric) now available

The DoseMe platform keeps growing. Methotrexate IV is now available for all users with a subscription to the chemotherapy package.

October 7, 2016

DoseMe Crunch to launch at HISA Data Analytics conference 11-12 October

DoseMe will launch DoseMe Crunch, a new clinical data analytics solution at next week’s HISA Health Data Analytics conference in Brisbane.
Read the PulseIT article…

September 13, 2016

Success sets DoseMe up for U.S. market

The Tech Street Journal shares the DoseMe story from backyard BBQ through to the DoseMe prototype and first stages of user feedback.
Read the article...

See More News and Updates...

Partners and Customers